On the stock market since 2021, it operates in the world of health and science. It has 2,440 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 8% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
The cash-and-debt balance is neither shiny nor alarming.
Clearly above the class average — a step short of the very top.
There is growth, but not at top-of-the-class tempo.
The stock has been running stronger than the market lately.
No real weak spot in any of the five subjects — a balanced report card.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 30% below its peak. The market has trimmed its expectations for the company.
The company sells $853.7M a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 12 buys and 8 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $13.00 — 21% above today’s price.
A loss of $30.3M against $853.7M in annual sales.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
On our five-subject report card, INNV sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: INNV has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.